Mutated anti-CD22 antibodies and immunoconjugates

Details for Australian Patent Application No. 2004293471 (hide)

Owner The Government of the United States, as represented by the Secretary of Health and Human Services

Inventors Bang, Sook-Hee; Pastan, Ira H.; Ho, Mitchell

Agent Pizzeys

Pub. Number AU-B-2004293471

PCT Pub. Number WO2005/052006

Priority 60/525,371 25.11.03 US

Filing date 24 November 2004

Wipo publication date 9 June 2005

Acceptance publication date 8 July 2010

International Classifications

C07K 14/705 (2006.01) Peptides having more than 20 amino acids

A61K 47/48 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

C07K 16/28 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Event Publications

15 June 2006 PCT application entered the National Phase

  PCT publication WO2005/052006 Priority application(s): WO2005/052006

8 July 2010 Application Accepted

  Published as AU-B-2004293471

4 November 2010 Application for Amendment

  The nature of the amendment is as shown in the statement(s) filed 09 Jul 2010. Address for service in Australia - Pizzeys Patent and Trade Mark Attorneys Level 14, ANZ Centre 324 Queen Street Brisbane QLD 4000

24 February 2011 Amendment Made

  The nature of the amendment is as shown in the statement(s) filed 09 Jul 2010

3 March 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004293474-Reduction of dermal scarring

2004293464-Quinazolinone compounds as anticancer agents